Publications by authors named "Alice Marceau-Renaut"

Article Synopsis
  • The study examines the blood-related characteristics and overall prognosis of 127 patients with telomere biology disorders (TBD) who were diagnosed after age 15, highlighting a lack of data on this topic.
  • At diagnosis, significant haematological issues were present in nearly 76% of patients, with bone marrow failure (BMF) being the most common, affecting 46.5% of the cases, while some patients also developed additional complications over time.
  • The findings suggest that BMF patients tend to be younger and have a better survival rate compared to those with higher-risk blood cancers, indicating TBD as a complex multi-organ disease needing further research on its evolutionary nature and outcomes.
View Article and Find Full Text PDF

We investigated using a custom NGS panel of 149 genes the mutational landscape of 64 consecutive adult patients with tyrosine kinase fusion-negative hypereosinophilia (HE)/hypereosinophilic syndrome (HES) harboring features suggestive of myeloid neoplasm. At least one mutation was reported in 50/64 (78%) patients (compared to 8/44 (18%) patients with idiopathic HE/HES/HE used as controls; p < .001).

View Article and Find Full Text PDF

Tandem duplications (TDs) of the UBTF gene have been recently described as a recurrent alteration in pediatric acute myeloid leukemia (AML). Here, by screening 1946 newly diagnosed adult AML, we found that UBTF-TDs occur in about 3% of patients aged 18-60 years, in a mutually exclusive pattern with other known AML subtype-defining alterations. The characteristics of 59 adults with UBTF-TD AML included young age (median 37 years), low bone marrow (BM) blast infiltration (median 25%), and high rates of WT1 mutations (61%), FLT3-ITDs (51%) and trisomy 8 (29%).

View Article and Find Full Text PDF

Objectives: Acute myeloid leukemia (AML) with inv(16)/t(16;16) is among the most frequent AML subtypes. It is recognized by the detection of the fusion which confers a favorable prognosis, irrespective of the presence of secondary cytogenetic abnormalities. However, the effect of additional genetic anomalies on the behavior of inv(16) AML is debatable.

View Article and Find Full Text PDF

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a newly described entity linked to somatic mutation of UBA1, encompassing inflammatory disorders and hematological malignancies. Patients experiments symptoms related to inflammatory manifestations on the skin, joints, lungs. Most patients are refractory to usual anti-inflammatory or immunosuppressive treatments.

View Article and Find Full Text PDF
Article Synopsis
  • BET inhibitors (BETi) like OTX015 and JQ1 show promise against AML, but their detailed effects haven't been fully explored yet.
  • The combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) is effective in AML, as both BETi and ATO + ATRA can promote cell differentiation and apoptosis.
  • Preclinical findings indicate that BETi may work by degrading the NPM1c protein and altering the balance with BRD4 in cells, while some AML cell lines, like IMS-M2, exhibit resistance due to certain genetic pathways.
View Article and Find Full Text PDF

WT1 overexpression is frequently identified in acute myeloid leukemia (AML) and has been reported to be a potential marker for monitoring measurable residual disease (MRD). We evaluated the use of postinduction WT1 MRD level as a prognostic factor, as well as the interaction between postinduction WT1 MRD response and the effect of allogeneic stem cell transplantation (allo-SCT) in the first complete remission (CR). In the ALFA-0702 trial, patients with AML, aged 18 to 59, had a prospective quantification of WT1 MRD.

View Article and Find Full Text PDF
Article Synopsis
  • Researchers studied 471 patients aged 60 or older with a type of leukemia called acute myeloid leukemia (AML) to create a tool that predicts how long they might survive after treatment.
  • They found that certain gene mutations in these patients affected their chances of survival, especially for those with poor genetic conditions.
  • The new decision tool can help doctors figure out the best treatment plans based on the patients' genetic info and can be used in future clinical trials.
View Article and Find Full Text PDF
Article Synopsis
  • * A study of 120 ECD patients revealed that 42.5% had signs of clonal hematopoiesis, and 15.8% developed serious blood cancers, mostly myeloid neoplasms, with common mutations identified in genes like TET2 and ASXL1.
  • * Patients with clonal hematopoiesis tend to be older, often have involvement of retroperitoneal organs, and are more likely to have BRAFV600E mutations; the findings suggest that clonal
View Article and Find Full Text PDF
Article Synopsis
  • Older age and preexisting health issues are risk factors for severe COVID-19, and recent studies suggest that clonal hematopoiesis (CH) may also play a role in chronic inflammation and aging-related diseases.
  • This study aimed to explore the biological factors linked to clinical deterioration in COVID-19 patients, particularly focusing on white blood cell types and inflammatory markers to see if CH influenced their condition.
  • Among 122 hospitalized COVID-19 patients, findings revealed that higher white blood cell counts and CRP levels were associated with the need for orotracheal intubation, but the presence of CH did not significantly affect patient outcomes like intubation requirements or mortality.
View Article and Find Full Text PDF

Context: Acute myeloid leukemia (AML) is a rare disease in children, with only 50% to 60% event-free survival. Among patients with AML, 10% do not respond to first-line chemotherapy. There is no recommendation concerning second-line treatments.

View Article and Find Full Text PDF

Acute myeloid leukemia (AML) encompasses heterogeneous entities with dismal outcomes. Intermediate and unfavorable-risk AML represent the most difficult-to-treat entities. We recently reported the benefit of the clofarabine-based consolidation (CLARA) regimen compared to the standard high-dose cytarabine (HDAC) regimen in younger AML patients.

View Article and Find Full Text PDF

Acute myeloid leukemia (AML) is a highly heterogeneous disease both in terms of genetic background and response to chemotherapy. Although molecular aberrations are routinely used to stratify AML patients into prognostic subgroups when receiving standard chemotherapy, the predictive value of the genetic background and co-occurring mutations remains to be assessed when using newly approved antileukemic drugs. In the present study, we retrospectively addressed the question of the predictive value of molecular events on the benefit of the addition of gemtuzumab ozogamicin (GO) to standard front-line chemotherapy.

View Article and Find Full Text PDF